Shionogi & Co., Ltd. (TSE:4507) has raised its dividend forecast for the 2026 March fiscal year, citing strong growth in its HIV business and positive clinical trial results for new drugs.
| Item | Before | After | Change |
|---|---|---|---|
| Year-end Dividend | 33.00 | 38.00 | +5.00 (15.15%) |
| Annual Dividend | 66.00 | 71.00 | +5.00 (7.58%) |
| Year-end Dividend | 33.00 | 38.00 | +5.00 (15.15%) |
The revision reflects improved earnings from the HIV business, driven by steady market penetration of LAI formulations. Positive clinical trial outcomes for new drugs have strengthened the company’s revenue base, while business investments have bolstered operational performance. The decision also considers the company’s financial position and STS2030 Revision shareholder return metrics, including EPS, DOE, and ROE.
The dividend increase underscores Shionogi’s commitment to shareholder returns and signals confidence in its long-term growth strategy. Investors may view the move as a reflection of the company’s solid financial health and strategic progress.